Oncolytics Biotech Inc (ONCY)
1.04
0.00 (0.00%)
USD |
NASDAQ |
Apr 23, 16:00
1.05
+0.01
(+0.96%)
Pre-Market: 20:00
Oncolytics Biotech Cash from Financing (TTM)
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2022 | 9.381M |
| September 30, 2022 | 4.931M |
| June 30, 2022 | 3.389M |
| March 31, 2022 | 10.43M |
| December 31, 2021 | 26.33M |
| September 30, 2021 | 34.68M |
| June 30, 2021 | 38.75M |
| March 31, 2021 | 35.94M |
| December 31, 2020 | 29.68M |
| September 30, 2020 | 28.33M |
| June 30, 2020 | 28.44M |
| March 31, 2020 | 26.37M |
| December 31, 2019 | 15.83M |
| September 30, 2019 | 9.871M |
| June 30, 2019 | 7.269M |
| March 31, 2019 | 12.92M |
| December 31, 2018 | 10.26M |
| September 30, 2018 | 9.464M |
| June 30, 2018 | 9.864M |
| March 31, 2018 | 10.31M |
| December 31, 2017 | 9.886M |
| September 30, 2017 | 9.643M |
| June 30, 2017 | 8.590M |
| March 31, 2017 | 0.7873M |
| December 31, 2016 | 0.722M |
| Date | Value |
|---|---|
| September 30, 2016 | 1.181M |
| June 30, 2016 | 0.0196M |
| March 31, 2016 | 5.094M |
| December 31, 2015 | 18.54M |
| September 30, 2015 | 20.30M |
| June 30, 2015 | 23.81M |
| March 31, 2015 | 20.49M |
| December 31, 2014 | 8.192M |
| September 30, 2014 | 6.234M |
| June 30, 2014 | 3.265M |
| March 31, 2014 | 0.5157M |
| December 31, 2013 | 29.52M |
| September 30, 2013 | 29.21M |
| June 30, 2013 | 30.05M |
| March 31, 2013 | 30.71M |
| December 31, 2012 | 20.85M |
| September 30, 2012 | 20.72M |
| June 30, 2012 | 20.21M |
| March 31, 2012 | 20.29M |
| December 31, 2011 | 14.99M |
| September 30, 2011 | 41.51M |
| June 30, 2011 | 41.63M |
| March 31, 2011 | 41.38M |
| December 31, 2010 | 26.46M |
| September 30, 2010 | 24.82M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
3.389M
Minimum
Jun 2022
38.75M
Maximum
Jun 2021
20.64M
Average
26.33M
Median
Dec 2021
Cash from Financing (TTM) Benchmarks
| Acasti Pharma Inc | 7.359M |
| Aurinia Pharmaceuticals Inc | -5.13M |
| Edesa Biotech Inc | 2.224M |
| Lexaria Bioscience Corp | 6.862M |
| Xenon Pharmaceuticals Inc | 353.52M |